Prognostic Significance of Plasma D-Dimer Levels in Patients with Lung Cancer

Yıl 2010, Cilt: 7 Sayı: 2, 155 - 160, 01.06.2010

Ahmet Ursavaş Mehmet Karadag Esra Uzaslan Selma Yesılkaya Funda Coskun Ercument Ege

Öz

Anahtar Kelimeler

-

Prognostic Significance of Plasma D-Dimer Levels in Patients with Lung Cancer

Öz

-

Anahtar Kelimeler

-

Kaynakça

• Rickles FR, Levine MN, Dvorak HF. Abnormalities of hemostasis in malignancy. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, Gearge JN (eds). Hemostasis and Thrombosis. Basic principles and clinical practice, 4th ed. Philedelphia: Lippincott Williams Wilkins; 2001: 1131-52.
• Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de I’Hotel Dieu de Paris, vol. 3 2nd edition, Ballière, Paris 1865:654-712.
• Kempin SJ. Hemostatic defects in cancer patients. Cancer Investigation 1997;15:23-36.
• Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 1999;25:167-72.
• Verheul HMW, Hockman K, Lupu F, et al. Platelet and coagulation activation with vascular endothelial growth factor generation in s oft tissue sarcomas. Clin Cancer Res 2000;6:166-71.
• Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001;3:371-84.
• Dupuy E, Habib A, Lebret M, Yang R, Levy-Toledano S, Tobelem G. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha. J Thromb Haemost 2003;1:1096-102.
• Verschuren F, Delvau N, Thys F. Simplify d-Dimer Assay for Pulmonary Embolism. Chest 2007;131:633-4.
• Ihara A, Kawamoto T, Matsumoto K, Shouno S, Morimoto T, Noma Y. Relationship between hemostatic factors and the platelet index in patients with ischemic heart disease. Pathophysiol Haemost Thromb 2006;35:388-91.
• Güneysel O, Pirmit S, Karakurt S. Plasma d-dimer levels increase with the severity of community acquired pneumonia. Tuberk Toraks 2004;52:341-7
• Wojtukiewicz MZ, Zacharski LR, Moritz TE, Hur K, Edwards RL, Rickles FR. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagul Fibrinolysis 1992;3:429-37.
• Seitz R, Rappe N, Kraus M, Immel A, Wolf M, Maasberg M, Egbring R, Pfab R, Havemann K. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis. 1993;4:249-54.
• Mountain CF. Revision in the international system for staging lung cancer. Chest 1997;111:1710-7.
• Kwaan HC, Keer HN. Fibrinolysis and cancer. Semin Thromb Hemost 1990;16:230-5.
• Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003;97:3044-52.
• Unsal E, Atalay F, Atikcan Ş, Yılmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004;98:93-8.
• Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglu E, Hatipoglu ON, Caglar T. High Plasma d-dimer Level is Associated with Decreased Survival in Patients with Lung Cancer. Clin Oncol (R Coll Radiol) 2007; [Epub ahead of print]
• Antoniou D, Pavlakou G, Stathopoulos GP, Karydis I, Chondrou E, Papageorgiou C, Dariotaki F, Chaimala D, Veslemes M. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer 2006;53:205-10.
• Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer Thorax 1997;52:563-5.
• Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 1994;74:38-45
• Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-35.
• Lee AYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine M. Comparison of low molecular weight heparine and coumarin derivates on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-9.
• Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-71.
• Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5.
• Di Nisio M, Klerk CP, Meijers JC, Buller HR. The prognostic value of the D-dimer test in cancer patients treated with and without low-molecular-weight heparin. J Thromb Haemost 2005;3:1531-3.